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Chloroquine-resistant 
Plasmodium vivax in 
Pakistan: an emerging 
threat
Pakistan has a population of 
194 million people, of which 
approximately 182 million live in 
malaria-endemic regions.1 In Pakistan 
there are 500 000 new cases of malaria 
and 50 000 deaths caused by malaria 
each year.2 Plasmodium vivax is the 
culprit in 88% of malaria admissions,1 
although Plasmodium falciparum often 
takes the spotlight, given its more 
severe course. Chloroquine has long 
been the drug offered to patients 
with unconﬁ rmed malaria and those 
diagnosed with P vivax infection. 
Given the rise of drug resistance in 
many infectious agents due to poorly 
regulated drug use, it is no surprise 
that resistance has occurred in the 
organism that so frequently infects us. 
The time has come to recognise the 
threat of chloroquine-resistant P vivax 
in Pakistan, an entity that has been 
largely ignored. 
Data on chloroquine resistance from 
Pakistan is scarce, even in the most 
recent global analysis.3 Nevertheless, 
in 2013, the emergence of the F1076L 
mutant of the pvmdr1 gene—the 
mutation responsible for chloroquine 
resistance—in P vivax in Pakistan 
highlights the imminent threat of 
resistant Plasmodium.4 In 2015, the 
ﬁ rst case of resistance was identiﬁ ed 
in a pregnant woman, and it was cured 
after switching to a combination of 
artemether and lumefantrine.5
Implementation of the Roll Back 
Malaria initiative by Pakistan’s 
Directorate of Malaria Control is 
the latest government attempt to 
eradicate malaria. It includes key 
elements of malaria control and 
prevention, but there is no mention of 
facilitating research on the Plasmodium 
gene polymorphisms in our 
population. We have reached an age 
of resistance, in which monotherapies 
and simple prevention are insuﬃ  cient 
to combat the new generation of 
genetically diverse microorganisms 
armed with mutations that we have 
not prepared for. Our national malaria 
policy addresses chloroquine-resistant 
P falciparum, ﬁ rst identiﬁ ed 30 years 
ago, but has no mention of resistant 
P vivax or management guidelines 
for resistant P vivax infections. Given 
the bleak future in the presence of 
a malaria parasite that is resistant 
to the most common drug, relevant 
government-funded research is 
necessary to understand the burden of 
resistant malaria in Pakistan, and old 
guidelines have to be revised before an 
epidemic takes control.
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